Université Grenoble-Alpes, Inserm 1036, Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Institut de Biosciences et Biotechnologies de Grenoble (BIG), Laboratoire Biologie du Cancer et de l'Infection (BCI), Grenoble 38000, France; Centre Hospitalier Universitaire de Grenoble, Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation- Centre d'étude et de conservation des œufs et du sperme humains (CECOS), La Tronche 38700, France; INSERM U1203, Equipe "Développement Embryonnaire Précoce Humain et Pluripotence", Institut de Médecine Régénératrice et de Biothérapie, Hôpital Saint-Eloi, Montpellier 34295, France.
Université Grenoble-Alpes, Inserm, Institute for Advanced Biosciences (IAB), équipe Génétique Epigénétique et Thérapie de l'Infertilité (GETI), Grenoble 38000, France; Centre Hospitalier Universitaire de Grenoble, Hôpital Couple Enfant, Département de Génétique et Procréation, Laboratoire de Génétique Chromosomique, La Tronche 38700, France.
Reprod Biomed Online. 2020 Jun;40(6):779-796. doi: 10.1016/j.rbmo.2020.02.002. Epub 2020 Feb 20.
Preimplantation genetic testing (PGT) is increasingly used worldwide. It currently entails the use of invasive techniques, i.e. polar body, blastomere, trophectoderm biopsy or blastocentesis, to obtain embryonic DNA, with major technical limitations and ethical issues. Evidence suggests that invasive PGT can lead to genetic misdiagnosis in the case of embryo mosaicism, and, consequently, to the selection of affected embryos for implantation or to the destruction of healthy embryos. Recently, spent culture medium (SCM) has been proposed as an alternative source of embryonic DNA. An increasing number of studies have reported the detection of cell-free DNA in SCM and highlighted the diagnostic potential of non-invasive SCM-based PGT for assessing the genetic status of preimplantation human embryos obtained by IVF. The reliability of this approach for clinical applications, however, needs to be determined. In this systematic review, published evidence on non-invasive SCM-based PGT is presented, and its current benefits and limitations compared with invasive PGT. Then, ways of optimizing and standardizing procedures for non-invasive SCM-based PGT to prevent technical biases and to improve performance in future studies are discussed. Finally, clinical perspectives of non-invasive PGT are presented and its future applications in reproductive medicine highlighted.
胚胎植入前遗传学检测(PGT)在全球范围内的应用日益广泛。目前,该检测需要使用侵入性技术,如极体、卵裂球、滋养外胚层活检或囊胚活检,以获取胚胎 DNA,但存在主要的技术限制和伦理问题。有证据表明,在胚胎嵌合的情况下,侵入性 PGT 可能导致遗传误诊,从而导致选择受影响的胚胎进行植入或破坏健康的胚胎。最近,已提出使用废弃的培养物(SCM)作为胚胎 DNA 的替代来源。越来越多的研究报告了在 SCM 中检测到游离 DNA,并强调了基于非侵入性 SCM 的 PGT 对评估通过 IVF 获得的人类胚胎遗传状况的诊断潜力。然而,这种方法在临床应用中的可靠性仍需确定。在本系统评价中,介绍了基于 SCM 的非侵入性 PGT 的现有证据,并与侵入性 PGT 进行了比较,探讨了其目前的优势和局限性。然后,讨论了优化和标准化基于 SCM 的非侵入性 PGT 程序的方法,以防止技术偏差并提高未来研究中的性能。最后,介绍了非侵入性 PGT 的临床前景及其在生殖医学中的未来应用。